# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA3821981 | Binding | Selectivity ratio of Ki for beta-catenin D145A mutant (138 to 686 residues)(unknown origin)/N-terminally fluorescein-labeled human BCL9 (350 to 375 residues) interaction to Ki for wild type beta-catenin (unknown origin)/N-terminally biotinylated human BCL9 (350 to 375 residues) interaction | Homo sapiens | 1 | ALA3817780 | assay format | Scientific Literature | |
2. | ALA3821982 | Binding | Inhibition of beta-catenin (unknown origin) expressed in HEK293 cells after 24 hrs by topflash dual luciferase reporter gene assay | Homo sapiens | 2 | ALA3817780 | cell-based format | Scientific Literature | |
3. | ALA3821983 | Binding | Competitive inhibition of wild type beta-catenin (unknown origin) expressed in Escherichia coli BL21 DE3 interaction with N-terminally biotinylated human BCL9 (350 to 375 residues) by alpha screen assay | Homo sapiens | 23 | ALA3817780 | assay format | Scientific Literature | |
4. | ALA3821984 | Binding | Competitive inhibition of wild type beta-catenin (unknown origin) expressed in Escherichia coli BL21 DE3 interaction with N-terminally biotinylated human E-cadherin (824 to 887 residues) by alpha screen assay | Homo sapiens | 1 | ALA3817780 | assay format | Scientific Literature | |
5. | ALA3821985 | Binding | Selectivity ratio of Ki for beta-catenin E155A mutant (138 to 686 residues)(unknown origin)/N-terminally fluorescein-labeled human BCL9 (350 to 375 residues) interaction to Ki for wild type beta-catenin (unknown origin)/N-terminally biotinylated human BCL9 (350 to 375 residues) interaction | Homo sapiens | 1 | ALA3817780 | assay format | Scientific Literature | |
6. | ALA3821986 | Binding | Competitive inhibition of N-terminally fluorescein-labeled human BCL9 (350 to 375 residues) interaction with beta-catenin E155A mutant (138 to 686 residues) (unknown origin) expressed in Escherichia coli BL21 DE3 after 3 hrs by fluorescence polarization assay | Homo sapiens | 1 | ALA3817780 | assay format | Scientific Literature | |
7. | ALA3821987 | Binding | Competitive inhibition of N-terminally fluorescein-labeled human BCL9 (350 to 375 residues) interaction with beta-catenin D145A/E155A double mutant (138 to 686 residues) (unknown origin) expressed in Escherichia coli BL21 DE3 after 3 hrs by fluorescence polarization assay | Homo sapiens | 1 | ALA3817780 | assay format | Scientific Literature | |
8. | ALA3821988 | Binding | Competitive inhibition of N-terminally fluorescein-labeled human BCL9 (350 to 375 residues) interaction with beta-catenin D145A mutant (138 to 686 residues) (unknown origin) expressed in Escherichia coli BL21 DE3 after 3 hrs by fluorescence polarization assay | Homo sapiens | 1 | ALA3817780 | assay format | Scientific Literature | |
9. | ALA3821989 | Binding | Selectivity ratio of Ki for wild type beta-catenin (unknown origin)/ N-terminally biotinylated human BCL9 (350 to 375 residues) interaction to Ki for wild type beta-catenin (unknown origin)/N-terminally biotinylated human E-cadherin (824 to 887 residues) interaction | Homo sapiens | 2 | ALA3817780 | assay format | Scientific Literature | |
10. | ALA3821990 | Binding | Inhibition of beta-catenin (unknown origin) expressed in HEK293 cells up to 100 uM after 24 hrs by fopflash dual luciferase reporter gene assay | Homo sapiens | 1 | ALA3817780 | cell-based format | Scientific Literature | |
11. | ALA3821991 | Functional | Cytotoxicity against Wnt-activated human SW480 cells assessed as reduction in cell viability after 72 hrs by MTS assay | Homo sapiens | 3 | ALA3817780 | cell-based format | Scientific Literature | |
12. | ALA3821992 | Functional | Cytotoxicity against Wnt-activated human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTS assay | Homo sapiens | 3 | ALA3817780 | cell-based format | Scientific Literature | |
13. | ALA3822128 | Functional | Cytotoxicity against Wnt-signaling latent human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay | Homo sapiens | 3 | ALA3817780 | cell-based format | Scientific Literature | |
14. | ALA3822129 | ADME | Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTS assay | Homo sapiens | 3 | ALA3817780 | cell-based format | Scientific Literature | |
15. | ALA3822130 | Functional | Selectivity ratio of IC50 for human A549 cells to IC50 for human SW480 cells | Homo sapiens | 2 | ALA3817780 | cell-based format | Scientific Literature | |
16. | ALA3822131 | Functional | Selectivity ratio of IC50 for human A549 cells to IC50 for human HCT116 cells | Homo sapiens | 2 | ALA3817780 | cell-based format | Scientific Literature | |
17. | ALA3822132 | ADME | Selectivity ratio of IC50 for HEK293 cells to IC50 for human SW480 cells | Homo sapiens | 2 | ALA3817780 | cell-based format | Scientific Literature | |
18. | ALA3822133 | ADME | Selectivity ratio of IC50 for human HEK293 cells to IC50 for human HCT116 cells | Homo sapiens | 2 | ALA3817780 | cell-based format | Scientific Literature | |
19. | ALA4052869 | ADME | Drug uptake in human MDA-MB-231 cells assessed per million cells at 20 uM in presence of 5% FBS after 24 hrs incubation by HPLC-MS analysis | Homo sapiens | 2 | ALA4052582 | cell-based format | Scientific Literature | |
20. | ALA4052873 | Functional | Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTS assay | Homo sapiens | 4 | ALA4052582 | cell-based format | Scientific Literature |